Literature DB >> 1879049

The use of nasal calcitonin spray in the treatment of hypercalcaemia of malignancy.

M Bower1, R C Stein, A Hedley, J Davenport, K Colston, R C Coombes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1879049     DOI： 10.1007/bf00685541

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  10 in total

1.  Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.

Authors:  S H Ralston; A A Alzaid; M D Gardner; I T Boyle
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-14

2.  Salmon calcitonin in the treatment of hypercalcemia.

Authors:  O L Silva; K L Becker
Journal:  Arch Intern Med       Date:  1973-09

3.  Treatment of hypercalcemia. Comparison of intravenously administered phosphate, sulfate, and hydrocortisone.

Authors:  D H Fulmer; A B Dimich; E O Rothschild; W P Myers
Journal:  Arch Intern Med       Date:  1972-06

4.  Mithramycin treatment of hypercalcemia.

Authors:  C P Perlia; N J Gubisch; J Wolter; D Edelberg; M M Dederick; S G Taylor
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

5.  Intranasal calcitonin and plasma calcium concentrations in normal subjects.

Authors:  A E Pontiroli; M Alberetto; G Pozza
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-11

6.  Single high dose aminohydroxypropylidene diphosphonate infusions to treat cancer-associated hypercalcaemia.

Authors:  B Cantwell; A L Harris
Journal:  Lancet       Date:  1986-01-18       Impact factor: 79.321

7.  Efficacy of oral administration of etidronate disodium in maintaining normal serum calcium levels in previously hypercalcemic cancer patients.

Authors:  Q S Ringenberg; P S Ritch
Journal:  Clin Ther       Date:  1987       Impact factor: 3.393

Review 8.  Hypercalcaemia--new mechanisms for old observations.

Authors:  J Waxman
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

9.  Analgetic activity of calcitonin in patients with painful osteolytic metastases of breast cancer. Results of a controlled randomized study.

Authors:  A Roth; K Kolarić
Journal:  Oncology       Date:  1986       Impact factor: 2.935

10.  Temporal interrelationships between the circadian rhythms of serum parathyroid hormone and calcium concentrations.

Authors:  M E Markowitz; S Arnaud; J F Rosen; M Thorpy; S Laximinarayan
Journal:  J Clin Endocrinol Metab       Date:  1988-11       Impact factor: 5.958
  10 in total
  4 in total

1.  Nasal human calcitonin for tumor-induced hypercalcemia.

Authors:  J C Dumon; A Magritte; J J Body
Journal:  Calcif Tissue Int       Date:  1992-07       Impact factor: 4.333

Review 2.  Musculoskeletal pain associated with corticosteroid therapy in cancer.

Authors:  Deborah A Frieze
Journal:  Curr Pain Headache Rep       Date:  2010-08

Review 3.  Comparative tolerability of drug therapies for hypercalcaemia of malignancy.

Authors:  N Zojer; A V Keck; M Pecherstorfer
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 4.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.